Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients-Reference-Cited by-同舟云学术

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

Published:2020-02-04 Issue:4 Volume:189 Page:661-671
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jakobsen Lasse H.¹²^ORCID,Ellin Fredrik³,Smeland Knut B.⁴,Wästerlid Tove⁵,Christensen Jacob H.⁶,Jørgensen Judit M.⁷,Josefsson Pär L.⁸,Øvlisen Andreas K.¹²,Holte Harald⁴⁹^ORCID,Blaker Yngvild N.⁹¹⁰,Grauslund Jacob H.¹¹,Bjørn Jon¹²,Molin Daniel¹³,Lagerlöf Ingemar¹⁴^ORCID,Smedby Karin E.⁵,Colvin Katherine¹⁵,Thanarajasingam Gita¹⁶^ORCID,Maurer Matthew J.¹⁷,Habermann Thomas M.¹⁶,Song Kevin W.¹⁸,Zhu Katie Y.¹⁸,Gerrie Alina S.¹⁸,Cheah Chan Y.¹⁹²⁰²¹,El‐Galaly Tarec C.¹²

Affiliation:

1. Department of Hematology Aalborg University Hospital Aalborg Denmark

2. Department of Clinical Medicine Aalborg University Aalborg Denmark

3. Department of Clinical Sciences Lund, Oncology Lund University Lund Sweden

4. Department of Oncology Oslo University Hospital Oslo Norway

5. Department of Medicine Solna Division of Clinical Epidemiology Karolinska Institutet, and Karolinska University Hospital Stockholm Sweden

6. Department of Hematology Odense University Hospital Odense Denmark

7. Department of Hematology Aarhus University Hospital Aarhus Denmark

8. Department of Hematology Herlev Hospital Herlev Denmark

9. KG Jebsen Centre for B‐cell malignancies Oslo Norway

10. Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway

11. Department of Hematology Roskilde Sygehus Roskilde Denmark

12. Department of Hematology Rigshospitalet Copenhagen Denmark

13. Experimental and Clinical Oncology Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

14. Division of Drug Research Department of Medical and Health Sciences Linköping University Linköping Sweden

15. Department of Haematology Sir Charles Gairdner Hospital Nedlands WA Australia

16. Division of Hematology Mayo Clinic Rochester MN USA

17. Department of Health Sciences Research Mayo Clinic Rochester MN USA

18. Leukemia/BMT Program of BC Centre for Lymphoid Cancer BC Cancer Vancouver Canada

19. Department of Hematology Sir Charles Gairdner Hospital Nedlands Australia

20. Department of Hematology Pathwest Laboratory Medicine WA Nedlands Australia

21. Medical School University of Western Australia Crawley Australia

Funder

National Institutes of Health

Kræftens Bekæmpelse

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16425

Reference49 articles.

1. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

2. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis

3. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

4. Adult Burkitt leukemia and lymphoma

5. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fitting parametric cure models in R using the packages cuRe and rstpm2;Computer Methods and Programs in Biomedicine;2022-11

2. Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy;Leukemia & Lymphoma;2022-02-19

3. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high‐grade B‐cell lymphoma;European Journal of Haematology;2022-02-02

4. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels;Cancer Research and Treatment;2021-07-15

5. Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study;Blood Cancer Journal;2021-05